Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

News

  • Home
  •  
  • News



  • Most Read
  • Latest Comments
  • Orthocell locks in Singaporean regulatory approval in international commercialisation push for nerve repair product
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Orthocell locks in Singaporean regulatory approval in international commercialisation push for nerve repair product
    • News

    Smart pain assessment app now used by more than half of Australia’s residential aged care providers
    Public
  • Orthocell locks in Singaporean regulatory approval in international commercialisation push for nerve repair product
    • News

    Fledgling fintech hopes millennials put their Douugh into micro-investing ‘super’ app
    Public
  • Orthocell locks in Singaporean regulatory approval in international commercialisation push for nerve repair product
    • News

    🎵 The knee bone’s connected to the… collagen rope device (?!)
    Public
  • Orthocell locks in Singaporean regulatory approval in international commercialisation push for nerve repair product
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Parkinson’s UK backs Pharmaxis with $5 million to slow the onset of incurable disease with ‘ground breaking’ trial
    • Review
    • September 1, 2022

Latest Articles

  • Orthocell locks in Singaporean regulatory approval in international commercialisation push for nerve repair product
    Orthocell locks in Singaporean regulatory approval in international commercialisation push for nerve repair product
    • News

    • News

    Coventry Group issues earnings upgrade amid strong business consolidation efforts

    Having focused on consolidating their industrial products businesses, Coventry Group (ASX: CYG) is seeing strong synergies realised from their efforts with its earnings for FY24 expected to be substantially up from the previous year, even with just a modest jump in revenue.  Just a few days on from the end of FY24, Coventry Group’s preliminary

    Read More
    Public
  • Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    • News

    Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback

    A new drug seeking to treat irritability associated with Autism Spectrum Disorder (ASD) could soon be making its way to clinical trials in healthy volunteers after Zelira Therapeutics (ASX: ZLD) concluded a positive round of discussions with the United States Food and Drug Administration (FDA) on a study design. The proposed clinical trials are for

    Read More
    Public
  • Fleetwood scores $40m Queensland government housing contract
    • News

    Fleetwood scores $40m Queensland government housing contract

    Setting a foundation and shaping Queensland housing market, construction company Fleetwood (ASX: FWD) has won a contract to design, build, and install 60 homes for the Queensland Department of Housing, Local Government, Planning and Public Works. This aligns with Fleetwood’s strategy to expand its presence in the social housing sector and contribute to solving the

    Read More
    Public
  • Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug
    • News

    Autism patient conditions improved after 12 weeks of treatment of Neurotech’s drug

    Can you make autistic people less autistic? Neurotech International (ASX: NTI) believes so based on data published from their Phase II/III clinical trial of NTI-164 which aims to treat Autism Spectrum Disorder (ASD).  ASD is a complex neurodevelopmental condition that can manifest in various ways. From challenges in social interactions, repetitive behaviours, and restricted interests,

    Read More
    Public
  • WhiteHawk swoops major client with bookmaker engagement for cyber risk controls
    • News

    WhiteHawk swoops major client with bookmaker engagement for cyber risk controls

    Positioned as a prime target for cybercriminals due to their potential exposure to money laundering and sports corruption, one of Australia’s largest bookmakers has beefed up their cyber defence by engaging with cybersecurity provider WhiteHawk (ASX: WHK).  The engagement will see WhiteHawk provide an independent cyber audit based on non-invasive monitoring for 12-months to identify,

    Read More
    Public
  • City Chic completes exit from US with Avenue sale to focus on AU/NZ and clearing debt
    • News

    City Chic completes exit from US with Avenue sale to focus on AU/NZ and clearing debt

    Plus-size clothing specialists City Chic Collective (ASX: CCX) has completed its departure from the US market having settled its divestment of its Avenue business to FullBeauty Brands, ending a troublesome period where marketing tailwinds were curbed by the pandemic and rise of online shopping.  This strategic divestment is part of a business restructure by City

    Read More
    Public
  • Lumos Diagnostics expands FebriDx distribution to Belgium
    • News

    Lumos Diagnostics expands FebriDx distribution to Belgium

    Lumos Diagnostics (ASX: LDX), known for its rapid point-of-care (POC) diagnostics tests, has expanded its partnership with Henry Schein Medical to add Belgium to its distribution list. This agreement makes FebriDx, a rapid test designed to differentiate viral from bacterial infections, accessible to Belgian healthcare professionals.  FebriDx delivers results in 10 minutes from a fingerstick

    Read More
    Public
  • Battery additives market being driven by automotive and electronics industry’s need for advanced batteries
    • News

    Battery additives market being driven by automotive and electronics industry’s need for advanced batteries

    According to TechSci Research report, “Global Battery Additives Market – Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028“, the global battery additives market has witnessed tremendous growth in recent years, reaching a valuation of USD 1.78 billion in 2022. The market is projected to continue its strong upward trajectory, posting a CAGR of 8.95%

    Read More
    Public
  • Selective breeding leads Murray Cod Australia to produce fish with 80% more biomass
    • News

    Selective breeding leads Murray Cod Australia to produce fish with 80% more biomass

    A collaboration between Murray Cod Australia (ASX: MCA) and the CSIRO that commenced in 2021 is yielding positive results for the aquaculture company that is breeding fish up to 80% larger through a selective breeding program to enhance food supply and commercial production efficiency. Ross Anderson, CEO of Murray Cod Australia, said, “Our selective breeding

    Read More
    Public
  • Illegal aliens beware, FBR’s bricklaying robot has arrived in the United States
    • News

    Illegal aliens beware, FBR’s bricklaying robot has arrived in the United States

    In the backdrop of illegal migration proving a critical battleground in the US Presidential race, illegal labour could soon be replaced by Hadrian X – the bricklaying robot developed by FBR (ASX: FBR) which has just arrived in the United States.  The arrival of Hadrian X after a two month voyage by sea comes as

    Read More
    Public
  • «
  • ‹
  • 29
  • 30
  • 31
  • 32
  • 33
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.